
Transfusão Permuta Parcial em Crianças e Jovens com Doença Falciforme: Comparação da Experiência Manual com o Procedimento Automatizado

Carlos ESCOBAR, Marta MONIZ, Pedro NUNES, Clara ABADESSO, Teresa FERREIRA, António BARRA, Anabela LICHTNER, Helena LOUREIRO, Alexandra DIAS, Helena ALMEIDA

ABSTRACT

Introduction: The benefits of manual versus automated red blood cell exchange have rarely been documented and studies in young sickle cell disease patients are scarce. We aim to describe and compare our experience in these two procedures.

Material and Methods: Young patients (≤ 21 years old) who underwent manual- or automated-red blood cell exchange for prevention or treatment of sickle cell disease complications were included. Clinical, technical and hematological data were prospectively recorded and analyzed.

Results: Ninety-four red blood cell exchange sessions were performed over a period of 68 months, including 57 manual and 37 automated, 63 for chronic complications prevention, 30 for acute complications and one in the pre-operative setting. Mean decrease in sickle hemoglobin levels was higher in automated-red blood cell exchange ($p < 0.001$) and permitted a higher sickle hemoglobin level decrease per volume removed ($p < 0.001$), while hemoglobin and hematocrit remained stable. Ferritin levels on chronic patients decreased 54%. Most frequent concern was catheter outflow obstruction on manual-red blood cell exchange and access alarm on automated-red blood cell exchange. No major complication or alloimmunization was recorded.

Discussion: Automated-red blood cell exchange decreased sickle hemoglobin levels more efficiently than manual procedure in the setting of acute and chronic sickle cell disease, with minor technical concerns mainly due to vascular access. The threshold of sickle hemoglobin should be individualized for clinical and hematological goals. In our cohort of young patients, the need for an acceptable venous access was a limiting factor, but iron-overload was avoided.

Conclusion: Automated red blood cell exchange is safe and well tolerated. It permits a higher sickle hemoglobin removal efficacy, better volume status control and iron-overload avoidance.

Keywords: Adolescent; Anemia; Sickle Cell; Child; Erythrocyte Transfusion/methods; Young Adult

RESUMO

Introdução: Os benefícios da transfusão permuta parcial manual versus automatizada encontram-se pouco documentados e existem poucos estudos em jovens com doença falciforme. Pretendemos descrever e comparar a nossa experiência com os dois procedimentos.

Material e Métodos: Foram incluídos jovens (≤ 21 anos) que realizaram transfusão permuta parcial-manual ou -automatizada para prevenção ou tratamento de complicações da doença falciforme. Dados clínicos, técnicos e valores hematológicos foram recolhidos de forma prospectiva e analisados.

Resultados: Realizaram-se 94 transfusões permuta parcial num período de 68 meses, 57 manuais e 37 automatizadas, 63 para prevenção de complicações crónicas, 30 para complicações agudas e uma no contexto pré-operatório. A redução média da hemoglobina S foi superior na transfusão permuta parcial-automatizada ($p < 0.001$) e permitiu uma redução de hemoglobina S por volume permutado superior ($p < 0.001$), mantendo valores de hemoglobina e hematocrito estáveis. Os valores de ferritina dos doentes crónicos diminuíram em 54%. A principal preocupação foi a obstrução do lúmen do cateter na transfusão permuta parcial-manual e os alarmes de pressão do acesso na transfusão permuta parcial-automatizada. Não houve complicações major nem aloimunização.

Discussão: A transfusão permuta parcial-automatizada reduziu a hemoglobina S de forma mais eficiente que a transfusão permuta parcial-manual em doentes com complicações da doença falciforme, existindo pequenos problemas relacionados com o acesso vascular. O valor alvo da hemoglobina S deve ser individualizado segundo a clínica e os objetivos hematológicos. Na nossa coorte de jovens, a necessidade de um acesso venoso aceitável foi a principal limitação, mas a sobrecarga de ferro foi evitada.


Palavras-chave: Adolescente; Adulto Jovem; Anemia Falciforme; Criança; Transfusão de Eritrócitos/métodos

INTRODUCTION

Sickle cell disease (SCD) is one of the commonest genetic disorders causing severe disease. To date no therapy is completely effective in the prevention and treatment of SCD complications. Transfusion in SCD aims to improve oxygen-carrying capacity while reducing the circulating level of sickle hemoglobin (HbS) and increasing...
hemoglobin A, thus reducing impaired erythropoiesis, hemolysis and vaso-occlusive events, which are the main contributors for complications of SCD.1

Red blood cell exchange (RBCX) in SCD removes abnormal red blood cells (RBC) and replaces them with donor RBCs, and is probably an underused technique. Compared to simple transfusion, RBCX prevents volume overload and viscosity rising, and is the only technique that rapidly decreases the levels of HbS.2

Indications for RCBX have been classified by the evidence-based guidelines of the American Society for Apheresis (ASFA) into 4 categories3, and are summarized in Table 1. However, other indications may be considered attending to current literature: recurrent acute chest syndrome and recurrent vaso-occlusive crisis not responsive to hydroxycarbamide, acute hepatic sequestration, leg ulcer, pulmonary hypertension, end-stage renal disease and progressive proliferative retinopathy.2,4-9

To date, the benefits of manual versus automated RBCX have rarely been documented and studies in young patients are scarce. The safety and tolerability profile of automated RCBX procedures have been extensively reported in single-center experiences showing a good profile in children and adults.10-13

We aim to describe our pediatric experience in the management of SCD complications with the use of an automated RBCX (A-RBCX) program and compare it to our previous manual partial RBCX (M-RBCX) experience.

MATERIAL AND METHODS
Patients and variables

We included all children and young adults (≤ 21 years old) with SCD who underwent manual or automated RBCX between January 2011 and August 2016 for prevention or treatment of complications of SCD.

Data were prospectively collected into a database as part of patient follow-up. Variables considered were: clinical (gender, age, weight, indication), laboratory (hematocrit-Htc, hemoglobin-Hb, HbS%, HbF%, platelet count), packed RBC use, technical data (ports, duration) and complications.

Indications and definitions

Our protocol for RBCX in SCD contemplates the following indications:

1) Acute SCD complications:
- Stroke: persistent neurological abnormality or transient symptoms accompanied by a new cerebral lesion on neuroimaging studies.
- Acute chest syndrome (ACS): infiltrate on x-ray (consolidation), accompanied by: chest pain, fever, tachypnea, wheezing or cough. Severity was considered when increased oxygen needs or mechanical respiratory support was started.
- Vaso-occlusive crisis (VOC) refractory to standard treatment: clinically assessed painful crisis with no adequate pain control after standard measures and optimized opioid perfusion.

2) Chronic SCD complications:
- Primary stroke prevention: when high blood flow velocities more than 200 cm/s on trans-cranial Doppler are detected.
- Secondary stroke prevention: after acute or overt stroke, as shown in neuroimaging studies (magnetic resonance / angiogram).
- Recurrent acute complications: VOC, ACS or priapism.

3) In the pre-operative setting of major surgery.

Other indications are considered and individualized after discussion with pediatric hematology consultants.

Goals for HbS level are under 30% for acute stroke and stroke prevention, and 30% -50% in the other acute and chronic complications.

Table 1 - Indications for therapeutic apheresis: ASFA 2010 categories4

<table>
<thead>
<tr>
<th>ASFA category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>Apheresis is accepted as first-line therapy, either as primary standalone treatment or in conjunction with other modes of treatment.</td>
</tr>
<tr>
<td>II</td>
<td>Apheresis is accepted as second-line therapy, either as primary standalone treatment or in conjunction with other modes of treatment.</td>
</tr>
<tr>
<td>III</td>
<td>Optimum role of apheresis therapy is not established. Decision making should be individual</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SCD complication</th>
<th>Acute RCBX</th>
<th>Chronic/ Non-acute RCBX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute stroke</td>
<td>I</td>
<td>II</td>
</tr>
<tr>
<td>Acute chest syndrome, severe</td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>Multisystem organ failure</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td>Severe intrahepatic cholestasis</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td>Priapism</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td>Stroke prevention with iron overload prevention</td>
<td>II</td>
<td></td>
</tr>
<tr>
<td>Vaso-occlusive pain</td>
<td>III</td>
<td></td>
</tr>
<tr>
<td>Presurgery</td>
<td>III</td>
<td></td>
</tr>
</tbody>
</table>
Procedure description

**Ethical considerations:** informed consent was obtained from the legal tutors or from the patient over 18 years old before the procedure.

Blood product preparation: extended blood group phenotyping [ABO, Rh(D,C,c,E,e), K, Jk(a), Jk(b), Fy(a), Fy(b) and others] and antibody screening was performed to each patient prior to RBCX. Packed RBC units used are HbS-negative, leucodepleted at the time of donation and irradiated (except in emergency setting). A limited donor policy and Duffy group genotyping (FYB gene) 14 for each patient is in place in our hospital Blood Bank, in collaboration with the Portuguese Institute for Blood and Transplantation (IPST, IP).

**Local and monitoring:** all patients were admitted to our Intensive Care unit and had clinical and continuous cardio-respiratory monitoring before, during and immediately after the procedure (heart rate, respiratory rate, oxygen saturation, blood pressure, temperature). When considered clinically necessary, more than one procedure was performed.

**Procedure:**
- Ports: a transfusion and blood removal port were placed. The type of venous access was recorded for each patient.
- Manual RBCX procedure: continuous isovolemic exchange, of venesected blood for 10 - 15 mL/kg of packed RBC and a concomitant saline infusion, aiming to maintain a low hematocrit similar to the patient's initial hematocrit. No limitation on patient weight is considered.
- Automated RBCX procedure: Spectra Optia® Apheresis System (Terumo BCT) with a dedicated RBCX kit is in place in our PICU since December 2014. Calcium citrate anticoagulation in a 13:1 ratio is used. Exchange or depletion+exchange (isovolemic hemodilution) protocol was used according to the patients initial Htc and clinical situation. A personalized priming of the circuit with 5% albumin or blood must be performed for patients with a programmed extracorporeal exchange volume over 10% - 15% of the total blood volume (Spectra Optia® Operators Manual, 2015).

**Laboratory tests:** previous to the procedure and four to eight hours after procedure a complete blood count, reticulocyte count, HbS and HbF levels were obtained. Ionized serum calcium was measured when symptoms of hypocalcemia were present. Serum ferritin was obtained prior to RBCX in chronic patients.

Outcomes

The primary outcome of the study was HbS level variation after M- and A-RBCX.

The secondary outcomes were: technique indications; effect of RBCX on Hb, hematocrit, platelet count and HbF level; packed RBC utilization and efficiency; technical concerns and complications associated with vascular access and RCBX procedure.

**Statistical analysis**

Data are presented as mean ± standard deviation (SD) when the distribution was normal and median (range) when not normal. Normality was assessed using Shapiro-Wilk test. Manual and automated procedures were compared. The comparison of continuous variables was accomplished with parametric test Student’s *t* test when normality was assured. The comparison of categorical data in two-way contingency tables was performed using Fisher test. Statistical significance level was set at *p* = 0.05. Statistical software SPSS for Windows v19.0 was used.

RESULTS

**Cohort characteristics and indication for RBCX**

Ninety-four RBCX sessions were performed in 16 patients over a period of 68 months. All patients were homozygous for HbS (HbSS) and with African family origin. The age ranged from 5 to 21 years old (median: 12 years old) and weight ranged 15 to 63 kg (median: 30 kg). Fifteen patients were taking hydroxicarbamide before RBCX.

The median number of procedures per patient was two (range: 1 - 48 sessions), with nine patients performing only one or two RBCX and seven patients had three or more RBCX sessions.

RBCX were manually performed in 57 sessions and 37 were automated. There were statistically significant differences in terms of age and weight in both groups. Gender distribution, chronic indication frequency, pre-RBCX hematological values and procedure duration were similar. The characteristics of each group are presented in Table 2.

In 63 cases the procedures were indicated for prevention

![Table 2 - Characteristics of RBCX groups](image-url)
of chronic complications, in 30 for acute complications and one procedure in the pre-operative setting of laparoscopic cholecystectomy. The chronic and acute indications for RBCX in our cohort are summarized in Table 3.

The median follow-up for chronic patients was six months (range: 2 - 60 months). One young adult patient with overt stroke and recurrent priapism episodes was lost to follow-up after five A-RBCX sessions.

**Vascular access**

The most common venous port used for blood removal was central venous catheter (CVC) (84 sessions, 89.4%). In ten cases of RBCX the same CVC with two lumens was used for both blood removal and transfusion, and in eight cases two CVC had to be placed. Peripheral access was only used for blood removal in two cases of M-RBCX and was tried in four cases of A-RBCX without success due to its low blood outflow. Peripheral venous access for transfusion was used in 44 sessions (46.8%).

Only one patient had long-term port placed for transfusion for secondary stroke prevention in RBCX program: one was used for 14 M-RBCX sessions before being removed due to infection and a second one was used for 18 sessions. In this same patient, an arteriovenous fistula (AVF) in the forearm was created as a venous access for RBCX and was used in three manual procedures for bleeding and transfusion before AVF thrombosis.

**Hematological outcomes**

The mean decrease in HbS levels was higher in A-RBCX procedures (-46% vs -27%; \( p < 0.001 \)) while hemoglobin and hematocrit remained stable in both procedures (Table 4). The platelet count was highly decreased during automated sessions when compared to manual procedure (-33% vs -20%; \( p < 0.001 \)) but platelet count lower than 100 000 / \( \text{mm}^3 \) did not occur. In 34 A-RBCX procedures HbF levels were recorded before and after the procedure, with a mean decrease of 47.6%.

Ferritin levels were recorded for the five patients on the chronic transfusion program. One patient with concomitant ulcerative colitis has persistent low ferritin values due to frequent gastro-intestinal bleeding, and was not considered. One patient presented with iron overload with ferritin levels over 1400 ng/mL at the start of the RBCX program and was treated with deferoxamine plus A-RBCX during one year with a reduction and stabilization of ferritin serum levels to 300 ng/mL. The other three patients had received simple transfusions prior to chronic A-RBCX and ferritin levels reduced (median: initial serum ferritin: 223 ng/mL, last ferritin value: 112 ng/mL, variation: -54%) after a median of five A-RBCX sessions.

**Packed red cell use and efficiency**

The mean blood consumption of packed RBC per patient weight was 10.5 ± 3.3 mL/kg in M-RBCX and 19.7 ± 6.2 mL/kg in A-RBCX (\( p < 0.001 \)). Isovolemic hemodilution

---

**Table 3 - Indications for RBCX in our cohort by technique**

<table>
<thead>
<tr>
<th></th>
<th>M-RBCX</th>
<th>A-RBCX</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Acute chest syndrome</td>
<td>21</td>
<td>9</td>
<td>30</td>
</tr>
<tr>
<td>Refractory VOC</td>
<td>10</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>ACS + refractory VOC</td>
<td>4</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Priapism</td>
<td>5</td>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>Acute stroke</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Extensive subgaleal hematoma due to extramedullary hematopoiesis</td>
<td>-</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Chronic complications</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary stroke prevention*</td>
<td>36</td>
<td>27</td>
<td>63</td>
</tr>
<tr>
<td>Primary stroke prevention</td>
<td>1</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td>Recurrent VOC</td>
<td>0</td>
<td>4</td>
<td>4</td>
</tr>
<tr>
<td>Recurrent priapism*</td>
<td>0</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Pre-operative</td>
<td>-</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

* one patient with both indications

---

**Table 4 - Hematological outcomes in manual and automated RBCX (Mean ± SD)**

<table>
<thead>
<tr>
<th></th>
<th>Pre-RBCX*</th>
<th>Post-RBCX</th>
<th>Variation</th>
<th>( p )-value (t-test)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>M-RBCX</td>
<td>A-RBCX</td>
<td>M-RBCX</td>
<td>A-RBCX</td>
</tr>
<tr>
<td>Hb (g/dL)</td>
<td>8.6 ± 0.6</td>
<td>8.4 ± 0.9</td>
<td>9.3 ± 0.7</td>
<td>8.6 ± 0.8</td>
</tr>
<tr>
<td>Htc (%)</td>
<td>24.4 ± 1.9</td>
<td>23.5 ± 2.5</td>
<td>25.4 ± 2.4</td>
<td>23.8 ± 2.1</td>
</tr>
<tr>
<td>HbS (%)</td>
<td>56.0 ± 9.2</td>
<td>66.3 ± 14.6</td>
<td>41.3 ± 11.1</td>
<td>35.8 ± 11.4</td>
</tr>
<tr>
<td>HbF (%)†</td>
<td>9.7 ± 4.2</td>
<td>10.9 ± 6.4</td>
<td>7.9 ± 4.0</td>
<td>5.6 ± 3.3</td>
</tr>
<tr>
<td>Platelets (10⁶/µL)</td>
<td>338 ± 49</td>
<td>393 ± 159</td>
<td>268 ± 47</td>
<td>256 ± 100</td>
</tr>
</tbody>
</table>

* simple transfusion previous to RBCX was performed in 14 cases; † values available for 34 procedures: 5 in M-RBCX & 29 in A-RBCX
A threshold for HbS level under 30% has been recommended for patients with complications of SCD.\textsuperscript{2} However, some authors agree that a higher threshold between 40\% - 50\% may be acceptable in patients without recurrence of stroke in the first 24 months, patients with only abnormal TCD results or patients with acute complications besides stroke.\textsuperscript{15,16} For patients with recurrent VOC a threshold of < 50\% has been proposed.\textsuperscript{2} Achieving a HbS level threshold of 30\% or less may be associated with higher blood requirements and more frequent RBCX procedures and in our opinion the HbS threshold should be individualized according with clinical goals, especially in the acute setting. The higher packed RBC volume needed to perform A-RBCX could represent a concern for blood banks in some centers.

A higher platelet removal in the automated technique could be a limitation to remove higher blood volumes, but in our cohort we did not find any severe thrombocytopenia. The clinical significance of the reduction HbF levels in patients enrolled in the chronic RBCX program is unknown, and should be further analyzed.

Regarding ACS treatment, the better control of hyperviscosity and volume status associated with RBCX favors the use of this technique instead of simple transfusion as the first-line therapy in moderate and severe cases, when a rapid decrease in HbS is needed, and also in patients with a high baseline Hb value.\textsuperscript{2,9,17}

Albeit not consensual, in our opinion RBCX should also be considered as an additional therapy for refractory pain due to VOC after optimization of opioid infusion. A higher depuration of opioids during the procedure should be taken into account and analgesia should be monitored, although in our experience we did not find it a relevant issue once improvement of complaints was registered a few hours after RBCX and opioids could be decreased.

For children and young adults included in chronic transfusion programs, the need for an acceptable venous access can be a limiting factor, with a high rate of central port placement.\textsuperscript{8,15} Moreover, sedation and expertise for central line insertion requires a trained healthcare team. In our institution, children on the chronic RBCX program are admitted to PICU for 24 hours or less to perform the procedure. Blood removal in RBCX requires a good blood outflow that we were not able to achieve with peripheral venous access, probably due to vein size and cannulation difficulties. In the experience of other authors, arteriovenous fistula, long-term dual lumen implantable ports or even peripheral access have proved successful in adults\textsuperscript{16,18} and children\textsuperscript{8} with SCD in chronic erythrocytapheresis programs. Our AVF attempt was not successful, probably due to the size of the patient, and a long-term single-port subcutaneous catheter was placed in this child.

Alloimmunization has been a frequently described complication of multiple transfusions in adults with SCD.\textsuperscript{9} This complication is especially important in countries like Portugal, with donors mainly of Caucasian origin and sickle cell patients of African origin. In our experience no cases of alloantibodies were found, probably due to an
extensive blood group matching and limited donor policy. Nevertheless, recent literature in SCD patients has proved that RBCX does not increase the risk of alloimmunization even though the blood requirement and donor exposure is higher.18-20

Although not a main endpoint of our study, ferritin levels of our patients on chronic RBCX were always in the normal range and so no iron-overload complications were observed. One patient needed chelation therapy with deferasirox, due to multiple single transfusions as part of the chronic transfusion program for secondary prevention of stroke that was performed before starting RCBX. After starting the monthly A-RBCX program a decrease in ferritin levels was observed and chelation therapy was stopped. Iron overload is directly associated with transfusion method and its duration,21 and can have serious long-term consequences during adulthood, including hepatic cirrhosis, cardiac damage, diabetes, hypogonadism and pulmonary hypertension.22-24 A-RBCX is the method that is associated with the lowest iron accumulation rate of all transfusion regimens24 and has also proved to be an effective method to reduce iron overload in chronically transfused patients.25 Prevention of iron overload instead of treating its consequences is a major health goal in our care for children with sickle cell disease.

Despite the fact that A-RBCX is easier to perform and less human resource consuming, it is not feasible in all settings due to the need of specific and expensive equipment. In this context, manual RBCX still has a role in centers without apheresis systems. In our experience, this is a feasible and safe procedure that can be readily performed in the setting of acute complications of SCD to lower HbS levels.26 However, in the long-term and whenever available, automated procedures should be preferred for their ability to maintain lower HbS values, to allow more spaced procedures and avoid iron-overload.1 Further studies should address other indications for RCBX, especially in the pediatric population where prevention should start as early as needed.

**CONCLUSION**

Partial red cell exchange was shown to be a safe and well tolerated technique for the prevention and treatment of complications of sickle cell disease in our cohort. A higher HbS removal efficacy, better volume status control and iron-overload avoidance makes automated RBCX a preferred technique than compared to manual partial RBCX and should always be preferred in long-term transfusion programs.

**PROTECTION OF HUMANS AND ANIMALS**

This study was conducted in accordance with the principles of the Declaration of Helsinki, ICH Guidelines for Good Clinical Practice and in full conformity with relevant regulations. Patients provided written informed consent for study participation. The study protocol was approved by the local ethics committee.

**DATA CONFIDENTIALITY**

The authors declare having followed the protocols in use at their working center regarding patients’ data publication.

**CONFLICTS OF INTEREST**

All authors report no conflict of interest.

**FUNDING SOURCES**

This work received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

---

**REFERENCES**


